Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine

[1]  H. Groen,et al.  Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Ming Liu,et al.  Integrated analysis of genome-wide DNA methylation and gene expression profiles identifies potential novel biomarkers of rectal cancer , 2016, Oncotarget.

[3]  K. Junker,et al.  Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development? , 2016, Journal of Cancer Research and Clinical Oncology.

[4]  M. Rodriguez-Ruiz,et al.  Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value , 2016, Tumor Biology.

[5]  L. Mell,et al.  Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review , 2016, PloS one.

[6]  G. Robinet,et al.  Targeted therapy for localized non-small-cell lung cancer: a review , 2016, OncoTargets and therapy.

[7]  G. Cancel-Tassin,et al.  A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. , 2016, Cancer treatment reviews.

[8]  P. Maxim,et al.  Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer , 2016, PloS one.

[9]  Kun‐Hsing Yu,et al.  Omics Profiling in Precision Oncology* , 2016, Molecular & Cellular Proteomics.

[10]  G. Yousef,et al.  Omics for personalized medicine: defining the current we swim in , 2016, Expert review of molecular diagnostics.

[11]  Gajendra P. S. Raghava,et al.  Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: A step towards personalized medicine , 2016, Scientific Reports.

[12]  Mingzhou Guo,et al.  The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer , 2016, Oncotarget.

[13]  D. Morris,et al.  Prognostic Value of Carcinoembryonic Antigen (CEA), AFP, CA19-9 and CA125 for Patients with Colorectal Cancer with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy. , 2016, Anticancer research.

[14]  Wei Zhang,et al.  Identification of diagnostic and prognostic biomarkers for cancer: Focusing on genetic variations in microRNA regulatory pathways (Review). , 2016, Molecular medicine reports.

[15]  R. Moreno-Sánchez,et al.  Understanding the cancer cell phenotype beyond the limitations of current omics analyses , 2016, The FEBS journal.

[16]  G. Milano.  Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations. , 2015, Chinese clinical oncology.

[17]  A. Azmi,et al.  Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition , 2015, Seminars in cancer biology.

[18]  R. Scott,et al.  miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer , 2015, International journal of molecular sciences.

[19]  Fudong Yu,et al.  Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients. , 2015, International journal of clinical and experimental pathology.

[20]  B. Foroutan.  Personalized Medicine: A Review with Regard to Biomarkers , 2015 .

[21]  Y. Hoshida,et al.  Cancer biomarker discovery and validation. , 2015, Translational cancer research.

[22]  B. Sirohi,et al.  Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study , 2015, Indian Journal of Surgical Oncology.

[23]  Theresa Zhang,et al.  Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.

[24]  B. Ramaswamy,et al.  Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials. , 2015, The oncologist.

[25]  M. Rosa.  Advances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized Medicine. , 2015, Cancer control : journal of the Moffitt Cancer Center.

[26]  Sarah Watson,et al.  Pragmatic issues in biomarker evaluation for targeted therapies in cancer , 2015, Nature Reviews Clinical Oncology.

[27]  M. Kalia,et al.  Biomarkers for personalized oncology: recent advances and future challenges. , 2015, Metabolism: clinical and experimental.

[28]  F. André,et al.  Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community? , 2014, Cancer treatment reviews.

[29]  Sung-Bae Kim,et al.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. , 2014, The Lancet. Oncology.

[30]  O. Gottesman,et al.  Implementation and utilization of genetic testing in personalized medicine , 2014, Pharmacogenomics and personalized medicine.

[31]  Sardul Singh Sandhu,et al.  Prognostic and Predictive Biomarkers in Cancer. , 2014, Current cancer drug targets.

[32]  D. Gilbert,et al.  Complex correlations: replication timing and mutational landscapes during cancer and genome evolution. , 2014, Current opinion in genetics & development.

[33]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[34]  F. Frueh,et al.  Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer , 2014, Clinical Cancer Research.

[35]  R. Pazdur,et al.  U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non–Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive , 2014, Clinical Cancer Research.

[36]  A. Awada,et al.  Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine. , 2014, Discovery medicine.

[37]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[38]  M. Lewandowska,et al.  Prognostic and Predictive Biomarkers: Tools in Personalized Oncology , 2014, Molecular Diagnosis & Therapy.

[39]  Sung-Bae Kim,et al.  A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. , 2013, European journal of cancer.

[40]  I. Rigoutsos,et al.  The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease , 2013, Cell Death and Differentiation.

[41]  M. Esteller,et al.  A prognostic DNA methylation signature for stage I non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Gary D Bader,et al.  Comprehensive identification of mutational cancer driver genes across 12 tumor types , 2013, Scientific Reports.

[43]  W van Elmpt,et al.  Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[44]  Jan Lubinski,et al.  MiRNA‐362‐3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer , 2013, International journal of cancer.

[45]  Roman K. Thomas,et al.  Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Eeles,et al.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.

[48]  S. Gabriel,et al.  Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. , 2013, Gastroenterology.

[49]  R. Finn,et al.  Current approaches and future directions in the treatment of HER2-positive breast cancer. , 2013, Cancer treatment reviews.

[50]  Richard Simon,et al.  Implementing personalized cancer genomics in clinical trials , 2013, Nature Reviews Drug Discovery.

[51]  J. Remon,et al.  Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. , 2013, Translational lung cancer research.

[52]  G. Romieu,et al.  Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer—Study BES 06 , 2013, Targeted Oncology.

[53]  E. Perez,et al.  RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer , 2013, Breast Cancer Research and Treatment.

[54]  W. Travis,et al.  New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  K. Schaser,et al.  Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[56]  Stefan Glück,et al.  Molecular Profiling for Breast Cancer: A Comprehensive Review , 2013, Biomarkers in cancer.

[57]  B. Al-Lazikani,et al.  Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance , 2012, Clinical pharmacology and therapeutics.

[58]  S Michiels,et al.  Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  W. Ni,et al.  Genetic Polymorphisms of GSTM1, GSTT1, and GSTP1 with Prostate Cancer Risk: A Meta-Analysis of 57 Studies , 2012, PloS one.

[60]  Aaron M. King,et al.  Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma , 2012, British Journal of Cancer.

[61]  G. Breier,et al.  Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients , 2012, Journal of Translational Medicine.

[62]  R. Stallings,et al.  Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers , 2012, Genome Biology.

[63]  M. Akyildiz,et al.  The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma , 2012, Hepatitis monthly.

[64]  T. Ørntoft,et al.  miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer , 2012, BMC Medical Genomics.

[65]  Bichlien Nguyen,et al.  Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients , 2012, Annals of Surgical Oncology.

[66]  Tae Won Kim,et al.  Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status , 2012, Investigational New Drugs.

[67]  R. Vyzula,et al.  Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab , 2012, International journal of oncology.

[68]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[69]  A. Großhennig,et al.  Personalized medicine using DNA biomarkers: a review , 2012, Human Genetics.

[70]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[71]  B. Heckman-Stoddard.  Oncology biomarkers: discovery, validation, and clinical use. , 2012, Seminars in oncology nursing.

[72]  Jeffrey T. Leek,et al.  Personalized medicine: Keep a way open for tailored treatments , 2012, Nature.

[73]  M. Zabel,et al.  [Circulating tumor cells (CTCs)--clinical significance in patients with ovarian cancer]. , 2012, Ginekologia polska.

[74]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[75]  R. Gelber,et al.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial , 2012, The Lancet.

[76]  C. von Kalle,et al.  Recent Developments and Future Perspectives of Personalized Oncology , 2012, Oncology Research and Treatment.

[77]  P. Workman,et al.  Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. , 2012, Annual review of pharmacology and toxicology.

[78]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[79]  S. Powell,et al.  BRCA1 and BRCA2: different roles in a common pathway of genome protection , 2011, Nature Reviews Cancer.

[80]  Daniela Cilloni,et al.  Molecular Pathways: BCR-ABL , 2011, Clinical Cancer Research.

[81]  Richard W Tothill,et al.  Next-generation sequencing for cancer diagnostics: a practical perspective. , 2011, The Clinical biochemist. Reviews.

[82]  J. Ioannidis,et al.  STrengthening the Reporting of OBservational studies in Epidemiology: Molecular Epidemiology STROBE-ME. An extension of the STROBE statement , 2011, Journal of Epidemiology & Community Health.

[83]  E. Perez,et al.  Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437 , 2011, Clinical Cancer Research.

[84]  J. Ioannidis,et al.  STrengthening the Reporting of OBservational studies in Epidemiology – Molecular Epidemiology (STROBE-ME): An Extension of the STROBE Statement , 2011, European Journal of Epidemiology.

[85]  P. Voon,et al.  Tumour genetics and genomics to personalise cancer treatment. , 2011, Annals of the Academy of Medicine, Singapore.

[86]  J. Blay,et al.  Added value of molecular targeted agents in oncology. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[88]  Merrill Goozner,et al.  Duke scandal highlights need for genomics research criteria. , 2011, Journal of the National Cancer Institute.

[89]  J. Ross,et al.  Cancer biomarkers, companion diagnostics and personalized oncology. , 2011, Biomarkers in medicine.

[90]  K. Cheung,et al.  Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy. , 2011, Breast.

[91]  M. Esteller.  Epigenetic changes in cancer , 2011, F1000 biology reports.

[92]  Charles Swanton,et al.  Genetic prognostic and predictive markers in colorectal cancer , 2011, Nature Reviews Cancer.

[93]  J. Squire,et al.  PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer , 2011, BJU international.

[94]  Fatih Ozsolak,et al.  RNA sequencing: advances, challenges and opportunities , 2011, Nature Reviews Genetics.

[95]  P. M. Das,et al.  Downregulation of miR-342 is associated with tamoxifen resistant breast tumors , 2010, Molecular Cancer.

[96]  J. Błasiak,et al.  Efficacy of DNA double-strand breaks repair in breast cancer is decreased in carriers of the variant allele of the UBC9 gene c.73G>A polymorphism. , 2010, Mutation research.

[97]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[98]  Pawel Domagala,et al.  Immunophenotypic predictive profiling of BRCA1-associated breast cancer , 2010, Virchows Archiv.

[99]  R. Bristow,et al.  Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer , 2010, Acta oncologica.

[100]  Yong Qian,et al.  Hybrid Models Identified a 12-Gene Signature for Lung Cancer Prognosis and Chemoresponse Prediction , 2010, PloS one.

[101]  S. Andelinović,et al.  Future perspectives of personalized oncology. , 2010, Collegium antropologicum.

[102]  G. Mills,et al.  Future of personalized medicine in oncology: a systems biology approach. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  I. Sohn,et al.  Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. , 2010, Lung cancer.

[104]  David N Louis,et al.  Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine , 2010, EMBO molecular medicine.

[105]  Maria P. Pavlou,et al.  Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer , 2010, Nature Reviews Cancer.

[106]  D. Burstein,et al.  A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. , 2010, Current drug targets.

[107]  Howard Y. Chang,et al.  Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.

[108]  F. J. Ramos,et al.  Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  P. Collas.  The Current State of Chromatin Immunoprecipitation , 2010, Molecular biotechnology.

[110]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[111]  Annuska M Glas,et al.  Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer , 2010, Biomarker insights.

[112]  W. Carney,et al.  Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  H. Willard,et al.  Genomic and personalized medicine: foundations and applications. , 2009, Translational research : the journal of laboratory and clinical medicine.

[114]  Saeed Sadeghi,et al.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  L. Mazzucchelli,et al.  Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.

[116]  A. Hart,et al.  Validation of 70-gene prognosis signature in node-negative breast cancer , 2009, Breast Cancer Research and Treatment.

[117]  A. Marchetti,et al.  The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. , 2009, The International journal of biological markers.

[118]  Sabine Tejpar,et al.  Implications for KRAS status and EGFR-targeted therapies in metastatic CRC , 2009, Nature Reviews Clinical Oncology.

[119]  G. Fontanini,et al.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer , 2009, British Journal of Cancer.

[120]  I. Nagtegaal,et al.  A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? , 2009, European journal of cancer.

[121]  S. Horvath,et al.  Global levels of histone modifications predict prognosis in different cancers. , 2009, The American journal of pathology.

[122]  R. Kelley,et al.  Drug development in advanced colorectal cancer: Challenges and opportunities , 2009, Current oncology reports.

[123]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[124]  B. Budowle,et al.  Extracting evidence from forensic DNA analyses: future molecular biology directions. , 2009, BioTechniques.

[125]  D. Cunningham,et al.  Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  F. J. Ramos,et al.  Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer. , 2008, Clinical colorectal cancer.

[127]  William D. Figg,et al.  Validation of Analytic Methods for Biomarkers Used in Drug Development , 2008, Clinical Cancer Research.

[128]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[129]  Robert Gray,et al.  Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  M. Stephens,et al.  RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. , 2008, Genome research.

[131]  A. Chinnaiyan,et al.  The discovery and application of gene fusions in prostate cancer , 2008, BJU international.

[132]  S. Hirota,et al.  Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202) , 2008, International Journal of Clinical Oncology.

[133]  E. D. de Vries,et al.  Prognostic versus predictive value of biomarkers in oncology. , 2008, European journal of cancer.

[134]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  E. Van Cutsem,et al.  KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[136]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[137]  R. Recker,et al.  Recent Advances in Proteomics and Cancer Biomarker Discovery , 2008, Clinical medicine. Oncology.

[138]  K. Bensalah,et al.  Challenges of cancer biomarker profiling. , 2007, European urology.

[139]  L. Seymour,et al.  Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  J. Jassem,et al.  BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer , 2007, PloS one.

[141]  Ian O Ellis,et al.  Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[143]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[144]  Jae K. Lee,et al.  Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study , 2007, Molecular Cancer Therapeutics.

[145]  Zhong Zheng,et al.  DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. , 2007, The New England journal of medicine.

[146]  P. Johnston,et al.  BRCA1, a potential predictive biomarker in the treatment of breast cancer. , 2007, The oncologist.

[147]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[148]  Jeremy J. W. Chen,et al.  A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.

[149]  K. Hagiwara,et al.  Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp , 2006, British Journal of Cancer.

[150]  F. Hirsch,et al.  Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  Steven Gutman,et al.  Opinion: The US Food and Drug Administration perspective on cancer biomarker development , 2006, Nature Reviews Cancer.

[153]  S. Shak,et al.  A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients , 2006, Breast Cancer Research.

[154]  M. Dowsett,et al.  Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[155]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[156]  N J Wald,et al.  Guidance on terminology , 2006, Journal of medical screening.

[157]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[158]  M. Berger,et al.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. , 2006, Cancer research.

[159]  Roman Rouzier,et al.  Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[161]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[162]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[163]  C. Vogel,et al.  Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. , 2005, Clinical breast cancer.

[164]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[165]  M Paesmans,et al.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.

[166]  B. Pasche,et al.  Role of TGF-β in cancer and the potential for therapy and prevention , 2004 .

[167]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[168]  David C. Atkins,et al.  Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[169]  N. Hynes,et al.  A new therapeutic antibody masks ErbB2 to its partners. , 2004, Cancer cell.

[170]  S. Chanock,et al.  SNPs in cancer research and treatment , 2004, British Journal of Cancer.

[171]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[172]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[173]  W. Isaacs,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Pathological and Molecular Aspects of Prostate Cancer Prostate Cancer Ii , 2022 .

[174]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[175]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[176]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[177]  John D Minna,et al.  Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[178]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[179]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[180]  P J Catalano,et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.

[181]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[182]  G. Giles,et al.  After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. , 2001, American journal of human genetics.

[183]  R K Jain,et al.  Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[184]  S. Gygi,et al.  Quantitative Proteome Analysis: Methods and Applications , 2000, Annals of the New York Academy of Sciences.

[185]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[186]  S. Martino,et al.  Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.

[187]  M. Loda,et al.  Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer , 2000, Oncogene.

[188]  S. Lakhani,et al.  The pathology of hereditary breast cancer. , 1999, Disease markers.

[189]  H. Rockette,et al.  Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[191]  S. Bates,et al.  Clinical applications of serum tumor markers. , 1991, Annals of internal medicine.

[192]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[193]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .

[194]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[195]  K P Dingemans,et al.  Mechanisms of metastasis. , 1979, Biochimica et biophysica acta.

[196]  David C Christiani,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[197]  D. Ahmadvand,et al.  Oligo-clonal nanobodies as an innovative targeting agent for cancer therapy: New biology and novel targeting systems. , 2017, Protein expression and purification.

[198]  Xinchen Sun,et al.  KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. , 2016, Oncotarget.

[199]  H. Kamel,et al.  Conventional and Promising Biomarkers for Prostate Cancer their Clinical Implication and Prospective Role , 2016 .

[200]  C. Doss,et al.  Molecular Dynamics: New Frontier in Personalized Medicine. , 2016, Advances in protein chemistry and structural biology.

[201]  K. Jain.  Role of Proteomics in the Development of Personalized Medicine. , 2016, Advances in protein chemistry and structural biology.

[202]  T. Zima,et al.  [Circulating tumor cells and prostate cancer prognosis]. , 2014, Casopis lekaru ceskych.

[203]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[204]  J. Feliu,et al.  Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. , 2013, Critical reviews in oncology/hematology.

[205]  G. Reifenberger,et al.  Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation , 2013, Neurology.

[206]  J. Barrett,et al.  Evidence-based laboratory medicine in oncology drug development: from biomarkers to diagnostics. , 2013, Clinical chemistry.

[207]  H. Katayama,et al.  Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. , 2013, Neoplasma.

[208]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[209]  E. Perez,et al.  Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group ( NCCTG ) trials , 2011 .

[210]  Personalized medicine: identifying the appropriate patient through biomarkers in oncology. , 2011, P & T : a peer-reviewed journal for formulary management.

[211]  R. Słomski,et al.  APC gene mutations causing familial adenomatous polyposis in Polish patients , 2010, Journal of Applied Genetics.

[212]  Richard Simon,et al.  Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. , 2010, Personalized medicine.

[213]  Geoffrey E. Hinton,et al.  Melting of Peridotite to 140 Gigapascals , 2010, Science.

[214]  J Figueras,et al.  Customized birthweight standards for a Spanish population. , 2008, European journal of obstetrics, gynecology, and reproductive biology.

[215]  William C Hahn,et al.  Oncogenic transformation and experimental models of human cancer. , 2008, Frontiers in bioscience : a journal and virtual library.

[216]  P. L. McCormack,et al.  Panitumumab: in metastatic colorectal cancer with wild-type KRAS. , 2008, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[217]  B. Pasche,et al.  Role of TGF-beta in cancer and the potential for therapy and prevention. , 2004, Expert review of anticancer therapy.

[218]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[219]  International Human Genome Sequencing Consortium.  Initial sequencing and analysis of the human genome , 2001, Nature.